Clinical significance of CTC enumeration on the Epic Sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients treated with AR signaling inhibitors (ARSi).

被引：0
|
作者：
Schonhoft, Joseph
Gill, Audrey
Graf, Ryon P.
Jendrisak, Adam
Barnett, Ethan
Benoliel, Hannah
Carbone, Emily
Tubbs, Alisa
Orr, Sarah
Byun, Jiyun
Wenstrup, Rick
Scher, Howard, I
机构：
[1] Epic Sci Inc, San Diego, CA USA
[2] Epic Sci, San Diego, CA USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5571
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
    Adashek, Jacob J.
    Jain, Rohit K.
    Zhang, Jingsong
    CELLS, 2019, 8 (08)
  • [32] Clinical utility of CLIA-grade AR-V7 testing in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Markowski, Mark Christopher
    Silberstein, John
    Eshleman, James R.
    Luo, Jun
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [33] Carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following chemotherapy and androgen pathway inhibitors.
    Sonpavde, Guru
    Schnell, Frederick M.
    Wang, Christopher G.
    Mooney, David James
    Nalk, Gurudatta
    Cantor, Alan
    Acosta, Edward P.
    Eltoum, Isam-Eldin
    Bolger, Graeme
    DeShazo, Mollie
    Saleh, Mansoor N.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Sequencing of chemotherapy and androgen-axis inhibitors (AAIs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Dhawan, Ravinder
    Yang, Tony
    Miao, Raymond
    Hennessy, Daniel
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Retrospective analysis of prognostic factors for survival in metastatic castration-resistant prostate cancer patients (mCRPC) treated with abiraterone.
    Biro, Krisztina
    Budai, Barna
    Szonyi, Marta
    Bodrogi, Istvan
    Kuronya, Zsofia
    Gyergyay, Fruzsina
    Nagyivanyi, Krisztian
    Geczi, Lajos
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [36] Adiposity and response to androgen signaling inhibition (ASI) in men with metastatic castration-resistant prostate cancer (mCRPC)
    Hahn, Andrew Warren
    Tidwell, Rebecca
    Surasi, Devaki Shilpa
    Pilie, Patrick Glen
    Frigo, Daniel
    Subudhi, Sumit Kumar
    Efstathiou, Eleni
    Zurita, Amado J.
    Tu Shi-Ming
    Chapin, Brian Francis
    Fogelman, David R.
    Starbuck, Michael W.
    Corn, Paul G.
    Aparicio, Ana
    McQuade, Jennifer Leigh
    Logothetis, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [37] Extension of bone marrow involvement and cytopenias in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Preto, Daniel D. Almeida
    Goncalves Prince Soares, Marcella de Oliveira
    Furlan Matos Alves, Wilson Eduardo
    de Lima, Marcos Alves
    Junior Neif, Joao Antonio
    Rosa Zucca, Luis Eduardo
    Carcano, Flavio Mavignier
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [38] The efficacy and safety of tinengotinib in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).
    Subudhi, Sumit Kumar
    Han, Weiqing
    Liao, Chih-Yi
    Zhang, Shun
    Dai, Tao
    Peng, Peng
    Sun, Caixia
    Wang, Hui
    Hennessy, Katie
    Fu, Ximei
    Yu, Yingying
    Wu, Yingtong
    Li, Qing
    Xu, Ruolan
    Huang, Peng
    Neo, Levin
    Wu, Frank
    Fan, Jean
    Piha-Paul, Sarina A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 133 - 133
  • [39] The Prostate Cancer Registry: Do patients with metastatic castration-resistant prostate cancer (mCRPC) differ according to metastatic status at diagnosis?
    Chowdhury, Simon
    Birtle, Alison J.
    Bjartell, Anders
    Costa, Luis
    Feyerabend, Susan
    Galli, Luca
    Kalinka-Warzocha, Ewa
    Kramer, Gero
    Lumen, Nicolaas
    Maroto, Pablo
    Matveev, Vsevolod B.
    Paiss, Thomas
    Spaeth, Dominique
    Antoni, Laurent
    Kiumper, Edwin
    Wapenaar, Robert
    Lee, Emma
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] Response to cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) poorly responding to docetaxel
    Angelergues, A.
    Bellmunt, J.
    Efstathiou, E.
    Gonzalez, I.
    Gyftaki, R.
    Delanoy, N.
    Ozguroglu, M.
    Flechon, A.
    Guillot, A.
    Le Moulec, S.
    Castellano, D.
    Esteban, E.
    Munarriz, J.
    Campos Balea, B.
    Ardavanis, A.
    Stefanou, D.
    Oudard, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S488 - S488
12345